Catalog No.S3002

Rivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM, respectively.

Price Stock Quantity  
In DMSO USD 300 In stock
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rivaroxaban Chemical Structure

Rivaroxaban Chemical Structure
Molecular Weight: 435.88

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Rivaroxaban is available in the following compound libraries:

Product Information

  • Compare Factor Xa Inhibitors
    Compare Factor Xa Products
  • Research Area

Product Description

Biological Activity

Description Rivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM, respectively.
Targets Factor Xa [1] Prothrombinase [1]
IC50 0.7 nM 2.1 nM
In vitro Rivaroxaban is an oral, direct inhibitor of Factor Xa (FXa), being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity with IC50 of 2.1 nM. Rivaroxaban also shows a similar affinity to purified human and rabbit FXa (IC50 0.7 nM and 0.8 nM, respectively), but a lesser potency against purified rat FXa (IC50 3.4 nM). Endogenous human and rabbit FXa in plasma is inhibited to a similar extent by Rivaroxaban (IC50 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 290 nM). [1] Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 μM in vitro. [2]
In vivo Rivaroxaban reduces venous thrombosis in a dose dependent manner (ED50 0.1 mg/kg i.v.) in a rat venous stasis model. Rivaroxaban reduces arterial thrombus formation in an arteriovenous (AV) shunt in rats (ED50 5.0 mg/kg p.o.) and rabbits (ED50 0.6 mg/kg p.o.). [1] Plasma pharmacokinetics of Rivaroxaban are linear across the investigated dose range (1-10 mg/kg in rats, 0.3-3 mg/kg in dogs). Plasma clearance is low: 0.4 L/kg/h in rats and 0.3 L/kg/h in dogs; the volume of distribution (V(ss)) is moderate: 0.3 L/kg in rats, and 0.4 L/kg in dogs. The elimination half-life after oral administration is short in both species (0.9-2.3 hours). [3]

Protocol(Only for Reference)

Kinase Assay: [1]

Factor Xa Activity The activity of Rivaroxaban against purified serine proteases is measured using chromogenic or fluorogenic substrates in 96-well microtiter plates. The enzymes are incubated with Rivaroxaban or its solvent, dimethyl sulfoxide (DMSO), for 10 minutes. The reactions are initiated by the addition of the substrate, and the color or fluorescence is monitored continuously at 405 nm using a Spectra Rainbow Thermo Reader, or at 630/465 nm using a SPECTRAfluor plus, respectively, for 20 minutes. Enzymatic activity is analyzed in the following buffers (final concentrations): human FXa (0.5 nM), rabbit FXa (2 nM), rat FXa (10 nM), or urokinase (4 nM) in 50 mM Tris–HCl buffer pH 8.3, 150 mM NaCl, and 0.1% bovine serum albumin (BSA); Pefachrome FXa (50–800 μM) or chromozym U (250 μM) with thrombin (0.69 nM), trypsin (2.2 nM), or plasmin (3.2 nM) in 0.1 μM Tris–HCl, pH 8.0, and 20 mM CaCl2; chromozym TH (200 μM), chromozym plasmin (500 μM), or chromozym trypsin (500 μM) with FXIa (1 nM) or APC (10 nM) in 50mM phosphate buffer, pH 7.4, 150 mM NaCl; and S 2366 (150 or 500 μM) with FVIIa (1 nM) and tissue factor (3 nM) in 50 mM Tris–HCl buffer,pH 8.0, 100 mM NaCl, 5 mM CaCl2 and 0.3% BSA, H-D-Phe-Pro-Arg-6-amino-1-naphthalene-benzylsulfonamide-H2O (100 μM) and measured for 3 hours. The FIXaβ/FX assay, comprising FIXaβ (8.8 nM) and FX (9.5 nM) in 50 mM Tris–HCl buffer, pH 7.4, 100 mM NaCl, 5 mM CaCl2 and 0.1% BSA, is started by the addition of I-1100 (50 μM), and measured for 60 minutes. The inhibitory constant (Ki) against FXa is calculated according to the Cheng–Prusoff equation. The IC50 is the amount of inhibitor required to diminish the initial velocity of the control by 50%.

Cell Assay: [2]

Cell lines Caco-2, wild-type, and P-gp-overexpressing LLC-PK1
Concentrations 0 - 100 μM
Incubation Time 2 hours
Method LLC-PK1 and L-MDR1 cells are seeded in 96-well culture plates with microporous polycarbonate inserts and grown for 4 days in the same medium as used for cell cultures but without vincristine. The medium is replaced every 2 days. Before running the assay, the culture medium is replaced by HBSS buffer supplemented with 10 mM HEPES. Rivaroxaban are dissolved in DMSO and diluted with transport buffer to the respective final test concentrations (final DMSO concentration is always 1%). For inhibitor studies, the inhibitor is added at the appropriate concentration. counted. After 2 hour incubation at 37 °C, samples are taken from both compartments and, after the addition of ammonium acetate buffer and acetonitrile, are analyzed by LC-MS/M

Animal Study: [1]

Animal Models Fasted, male Wistar rats (HsdCpb:WU) and fasted, female New Zealand White rabbits (Esd:NZW).
Formulation Rivaroxaban dissolves in polyethylene glycol/H2O/ glycerol (996 g/100 g/60 g) and is given by i.v. Rivaroxaban dissolved in solutol/ethanol/H2O [40%/10%/50% (v/v/v)] and is given by p.o.
Dosages ≤0.3 mg/kg for i.v. and ≤3 mg/kg for p.o.
Administration Administered via i.v. or p.o.
Solubility 0.5% methylcellulose/0.2% Tween 80, 5 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.
Body Surface Area (m2)
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Perzborn E, et al. J Thromb Haemost, 2005, 3(3), 514–521.

[2] Gnoth MJ, et al. J Pharmacol Exp Ther, 2011, 338(1), 372-380.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2015-03-23)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02168829 Not yet recruiting Atrial Fibrillation|Stroke Ottawa Heart Institute Research Corporation|Canadian Inst  ...more Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR) September 2015 Phase 4
NCT02303795 Not yet recruiting Valvular Heart Disease Hospital do Coracao August 2015 Phase 2
NCT02273700 Not yet recruiting Atrial Fibrillation Centre Hospitalier Universitaire de Nīmes June 2015 --
NCT02387229 Not yet recruiting ATRIAL FIBRILLATION Montreal Heart Institute|Canadian Stroke Prevention Inter  ...more Montreal Heart Institute|Canadian Stroke Prevention Intervention Network (C-SPIN)|The Montreal Health Innovations Coordinating Center (MHICC)|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma March 2015 Phase 3
NCT02293395 Not yet recruiting Acute Coronary Syndrome Janssen Research & Development, LLC|Bayer|Duke Clinical R  ...more Janssen Research & Development, LLC|Bayer|Duke Clinical Research Institute|Harvard Medical School February 2015 Phase 2

view more

Chemical Information

Download Rivaroxaban SDF
Molecular Weight (MW) 435.88


CAS No. 366789-02-8
Storage 3 years -20℃Powder
6 months-80℃in solvent (DMSO, water, etc.)
Synonyms BAY 59-7939
Solubility (25°C) * In vitro DMSO 87 mg/mL (199.59 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Factor Xa Products

  • AGI-6780

    AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.

  • INCB024360

    INCB024360 is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2.

  • U73122

    U73122 is a potent phospholipase C (PLC) inhibitor, which reduces agonist-induced Ca2+ increases in platelets and PMN.

  • Apixaban

    Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.

    Features:A highly selective, reversible, and direct factor Xa inhibitor.

  • Ozagrel

    Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM.

  • Edoxaban

    Edoxaban is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.

  • Pemetrexed

    Pemetrexed is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively.

  • Methotrexate

    Methotrexate is an antimetabolite and antifolate drug, which acts by inhibiting the metabolism of folic acid.

  • Lonafarnib

    Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Phase 3.

  • Sildenafil Citrate

    Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction.

Recently Viewed Items

Tags: buy Rivaroxaban | Rivaroxaban ic50 | Rivaroxaban price | Rivaroxaban cost | Rivaroxaban solubility dmso | Rivaroxaban purchase | Rivaroxaban manufacturer | Rivaroxaban research buy | Rivaroxaban order | Rivaroxaban mouse | Rivaroxaban chemical structure | Rivaroxaban mw | Rivaroxaban molecular weight | Rivaroxaban datasheet | Rivaroxaban supplier | Rivaroxaban in vitro | Rivaroxaban cell line | Rivaroxaban concentration | Rivaroxaban nmr
Contact Us